Literature DB >> 2939211

Serotonin and the blood vessel wall.

P M Vanhoutte, T F Lüscher.   

Abstract

Serotonin has complex effects on the cardiovascular system. In the intact animal it may cause increases or decreases of blood pressure and in isolated blood vessels contraction or relaxation depending on the species and vascular bed studied, the route of administration and the dosage used. Contractions evoked by the monoamine are mediated mainly by S2-serotonergic receptors on vascular smooth muscle; in addition, serotonin may act indirectly by amplifying the response to norepinephrine and other agonists, by displacing norepinephrine from adrenergic nerve terminals or releasing constrictor substance(s) from the endothelium. Dilatation in response to serotonin is mediated by endothelial and prejunctional S1-serotonergic receptors which pharmacologically resemble 5-HT1-binding sites. In hypertension, constrictor responses to serotonin are augmented, while the vasodilator effects of the monoamine are decreased. The constrictor response to serotonin is increased more than those to other agonists, suggesting a functional rather than a structural adaptation of the hypertensive blood vessel wall. In hypertension the turnover of circulating platelets, the major source of peripheral serotonin, is accelerated and the mechanisms for the removal of the monoamine are impaired. The functional changes of the blood vessel wall and platelets could play a role in the maintenance of the increased peripheral vascular resistance in chronic hypertension, and they could be involved in the pathogenesis of complications of the hypertensive process. The concept that serotonin plays a role in chronic hypertension is further supported by the antihypertensive properties of the S2-serotonergic antagonist, ketanserin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2939211

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  9 in total

1.  Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin.

Authors:  R Amstein; N Fetkovska; F Ferracin; A Pletscher; F R Bühler
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression.

Authors:  R Ramasubbu
Journal:  J Psychiatry Neurosci       Date:  1999-01       Impact factor: 6.186

3.  Differential effects of hormone therapy on serotonin, vascular function and mood in the KEEPS.

Authors:  L Raz; L V Hunter; N M Dowling; W Wharton; C E Gleason; M Jayachandran; L Anderson; S Asthana; V M Miller
Journal:  Climacteric       Date:  2015-12-10       Impact factor: 3.005

4.  The relevance of serotonin antagonism in the treatment of hypertension.

Authors:  A E Doyle
Journal:  Drugs       Date:  1988       Impact factor: 9.546

5.  Effect of ketanserin on cerebral blood flow autoregulation in healthy volunteers.

Authors:  J F Schmidt; K S Olsen; G Waldemar; B C Jørgensen; O B Paulson
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

6.  Comparison of ketanserin and enalapril in the treatment of mild-to-moderate essential hypertension.

Authors:  L S Malatino; B Stancanelli; G Greco; G Polizzi; G Assogna; C Zanna; G Tamburino
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

7.  Effects of serotonin and noradrenaline on superficial hand veins in patients with primary hypertension and in healthy volunteers.

Authors:  M Wolzt; E Schmidt; B Wagner; S Schuller-Petrovic; P A Kyrle; H G Eichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-11       Impact factor: 3.000

Review 8.  Platelets in inflammation: regulation of leukocyte activities and vascular repair.

Authors:  Angèle Gros; Véronique Ollivier; Benoît Ho-Tin-Noé
Journal:  Front Immunol       Date:  2015-01-06       Impact factor: 7.561

9.  A review of the serotonin transporter and prenatal cortisol in the development of autism spectrum disorders.

Authors:  Roselyn Rose'meyer
Journal:  Mol Autism       Date:  2013-10-08       Impact factor: 7.509

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.